Fujii Y, Saitoh Y, Tanaka H, Toyooka H
Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Japan.
Anesth Analg. 1999 Aug;89(2):476-9. doi: 10.1097/00000539-199908000-00043.
In a prospective, randomized, double-blinded study, we evaluated the efficacy of granisetron and ramosetron for preventing postoperative nausea and vomiting (PONV) in major gynecologic surgery. One hundred twenty patients, ASA physical status I or II, aged 23-65 yr, received i.v. granisetron 2.5 mg or ramosetron 0.3 mg (n = 60 each) at the end of surgery. A standard general anesthetic technique and postoperative analgesia were used. The incidence of a complete response, defined as no PONV and no need for another rescue medication, 0-3 h after anesthesia was 87% with granisetron and 90% with ramosetron; the corresponding incidence 3-24 h after anesthesia was 85% and 90%; the corresponding incidence 24-48 h after anesthesia was 70% and 92% (P < 0.05). No clinically serious adverse events due to the drugs were observed in any of the groups. In conclusion, prophylactic therapy with ramosetron is more effective than granisetron for the longterm prevention of PONV after major gynecologic surgery.
We compared the efficacy of granisetron and ramosetron for preventing postoperative nausea and vomiting in major gynecologic surgery. Prophylactic therapy with ramosetron was more effective than granisetron for preventing postoperative nausea and vomiting 24-48 h after anesthesia.
在一项前瞻性、随机、双盲研究中，我们评估了格拉司琼和雷莫司琼预防妇科大手术术后恶心呕吐（PONV）的疗效。120例年龄在23 - 65岁、ASA身体状况为I或II级的患者在手术结束时静脉注射2.5毫克格拉司琼或0.3毫克雷莫司琼（每组60例）。采用标准的全身麻醉技术和术后镇痛。定义为麻醉后0 - 3小时无PONV且无需使用其他解救药物的完全缓解发生率，格拉司琼组为87%，雷莫司琼组为90%；麻醉后3 - 24小时的相应发生率分别为85%和90%；麻醉后24 - 48小时的相应发生率分别为70%和92%（P < 0.05）。任何组均未观察到因药物引起的临床严重不良事件。总之，雷莫司琼预防性治疗在长期预防妇科大手术术后PONV方面比格拉司琼更有效。
我们比较了格拉司琼和雷莫司琼预防妇科大手术术后恶心呕吐的疗效。雷莫司琼预防性治疗在预防麻醉后24 - 48小时的术后恶心呕吐方面比格拉司琼更有效。
